Portfolio company
Beacon Therapeutics
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
2 investors
Sectors
About
This company develops ophthalmic gene therapies to restore vision for patients with rare and prevalent retinal diseases causing blindness.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Ray Therapeutics
The company develops optogenetic gene therapies to restore vision for patients with blinding retinal diseases.
Atsena
This clinical-stage gene therapy company develops genetic medicines to reverse or prevent blindness for patients with inherited retinal diseases.
Restore Vision
This clinical-stage biotechnology company develops visual restoration gene therapies to treat blindness caused by genetic retinal disorders for patients with retinitis pigmentosa.
Nightstar
This company develops gene therapies for patients with rare inherited retinal diseases that cause progressive blindness.
Cirrus Therapeutics
This company develops gene and cell therapies to treat age-related macular degeneration and chronic vision loss for patients with blinding eye diseases.
RhyGaze
This biotechnology company develops optogenetic gene therapies to restore vision for patients with retinal diseases causing blindness.
PulseSight Therapeutics
This company develops non-viral gene therapies for patients with severe eye diseases including age-related macular degeneration.
Ikarovec
This company develops bicistronic gene therapies to treat chronic ophthalmic diseases, such as age-related macular degeneration, for patients suffering from vision loss.